Hoth Therapeutics, INC 8-K filings

Rocket One Inc. received a Nasdaq delisting warning for failing to meet minimum bid price requirements, while simultaneously announcing its acceptance into the Seagate Partner Program to bolster its AI infrastructure strategy.

Rocket One Inc. announced an increase in its At-The-Market offering, potentially raising an additional $5.26 million.

Rocket One Inc. announced a strategic collaboration with Placeve Inc. and shared updated presentation materials detailing its AI semiconductor infrastructure development for defense, space, and edge computing.

Rocket One Inc. has officially regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing price above $1.00 for ten consecutive business days.

Rocket One Inc. announced the appointment of Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board to guide technical development in AI computing and memory hardware for space and defense.

Rocket One Inc. has increased its At-The-Market offering by up to an additional $6.83 million, supplementing shares already sold.

Rocket One Inc. has appointed Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for its AI Nanomagnetic Technology, aiming to advance its space and defense computing hardware.

Rocket One Inc. increased its at-the-market equity offering capacity by $2.66 million and announced its acceptance into the AMD AI Developer Program.

Hoth Therapeutics, Inc. has officially changed its name to Rocket One Inc. and will trade under the new ticker symbol RKTO, signaling a strategic pivot towards the space economy with a focus on AI chip technology.

Hoth Therapeutics is changing its name to Rocket One, Inc. and restructuring to focus on AI infrastructure and next-generation semiconductor technologies, acquiring exclusive rights to VCU-developed spintronic computing technologies.

Hoth Therapeutics, Inc. has established a new wholly-owned subsidiary, Rocket One Inc., to pursue opportunities in the space industry, focusing on nano rocket systems.

Hoth Therapeutics, Inc. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, with 180 days to regain compliance.

Hoth Therapeutics is resuming sales of its common stock under an existing At-The-Market (ATM) offering agreement with H.C. Wainwright & Co.

Hoth Therapeutics has raised $2 million in gross proceeds through a registered direct offering of common stock and concurrent private placement of warrants.

Hoth Therapeutics, Inc. will use new presentation materials to engage US government officials regarding its weight loss drug and broader therapeutic pipeline.

Hoth Therapeutics, a clinical-stage biopharmaceutical company, presented its robust pipeline targeting unmet patient needs across oncology, neurology, and dermatology.

Hoth Therapeutics' board approved expanding its treasury reserve strategy to include Ethereum and Solana, allowing purchases up to $1 million in digital assets.

Hoth Therapeutics secures CEO Robb Knie with a new employment agreement and files a PCT patent application for its HT-001 cancer side effect treatment.

Hoth Therapeutics, Inc. shareholders re-elected directors, ratified auditors, and approved an equity plan amendment at their 2025 annual meeting.

Hoth Therapeutics, Inc. has released new presentation materials highlighting positive preclinical and preliminary Phase 2a clinical data for its lead drug candidate, HT-001, aimed at treating dermatological side effects from EGFR inhibitor cancer therapies.

Hoth Therapeutics, Inc. announced it has regained full compliance with Nasdaq's minimum bid price requirement, resolving a significant listing issue.

Hoth Therapeutics, a clinical-stage biopharmaceutical company, has released presentation materials detailing its diverse pipeline of next-generation therapeutics targeting significant unmet patient needs across oncology, neurology, and dermatology, alongside key development milestones and a strong financial position to fund current programs.

Hoth Therapeutics has received a notification from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for continued listing.

Merveille.ai, a subsidiary of Hoth Therapeutics, Inc., has received confirmation from the U.S. Patent and Trademark Office regarding full payment of fees for an international patent application related to hair loss treatment and prevention.

Hoth Therapeutics reports positive interim data from its Phase 2a clinical trial, CLEER-001, showing a 50% reduction in pruritus for patients treated with HT-001.

Hoth Therapeutics has entered into a \$354,219 agreement with OnTargetx R&D Inc. for a toxicity study and announced restatements of prior financial statements due to errors in accounting for prepaid research and development expenses.

Hoth Therapeutics increases the potential proceeds from its at-the-market offering by an additional $5 million.

Hoth Therapeutics announces it has regained compliance with Nasdaq's minimum bid price requirement after its stock price remained above $1.00 for 10 consecutive business days.

Hoth Therapeutics has released presentation materials detailing their clinical and pre-clinical programs, targeting unmet medical needs across various therapeutic areas.

Hoth Therapeutics' board of directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset.